BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38368929)

  • 1. Whole-Body Positron Emission Tomography with
    Fertitta L; Jannic A; Zehou O; Bergqvist C; Ferkal S; Moryousef S; Lerman L; Mulé S; Luciani A; Bapst B; Ezzedine K; Ortonne N; Itti E; Wolkenstein P
    J Invest Dermatol; 2024 Feb; ():. PubMed ID: 38368929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J; Mautner VF; Adam G; Derlin T
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
    Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
    J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.
    Miettinen MM; Antonescu CR; Fletcher CDM; Kim A; Lazar AJ; Quezado MM; Reilly KM; Stemmer-Rachamimov A; Stewart DR; Viskochil D; Widemann B; Perry A
    Hum Pathol; 2017 Sep; 67():1-10. PubMed ID: 28551330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [
    Azizi AA; Slavc I; Theisen BE; Rausch I; Weber M; Happak W; Aszmann O; Hojreh A; Peyrl A; Amann G; Benkoe TM; Wadsak W; Kasprian G; Staudenherz A; Hacker M; Traub-Weidinger T
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28771999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1.
    Raad RA; Lala S; Allen JC; Babb J; Mitchell CW; Franceschi AM; Yohay K; Friedman KP
    World J Nucl Med; 2018; 17(4):241-248. PubMed ID: 30505221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
    Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
    Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Derlin T; Tornquist K; Münster S; Apostolova I; Hagel C; Friedrich RE; Wedegärtner U; Mautner VF
    Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
    Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
    J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
    Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plurifocal malignant peripheral nerve sheath tumor demonstrated by 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Bertagna F; Bosio G; Biasiotto G; Savelli G; Rodella C; Giubbini R; Rosenbaum J; Alavi A
    Jpn J Radiol; 2009 Oct; 27(8):320-3. PubMed ID: 19856228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
    Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
    World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of
    Cook GJR; Lovat E; Siddique M; Goh V; Ferner R; Warbey VS
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.